U.S. Alleges Shkreli Hid Control of Retrophin Shares
- Shkreli sparked outrage when company hiked price of drug
- Eight-count indictment adds conspiracy charge, shows e-mails
Martin Shkreli appears before a House Oversight and Government Reform Committee in Washington, D.C., on Feb. 4.
Photographer: Pete Marovich/BloombergThis article is for subscribers only.
Prosecutors filed new charges accusing Martin Shkreli of engaging in more illegal financial maneuvers at his former drug company Retrophin Inc. by using employees and consultants to conceal his control of stock.
The new eight-count indictment, adding a conspiracy charge, sheds more light on e-mail communications between Shkreli and a former corporate lawyer, Evan Greebel, who is accused of helping the notorious biotech founder cover up securities fraud.